Eyenovia Reports Q1 2025 Financial Results, Provides Merger and Optejet Development Update

HYPERION DEFI, INC.

2025-Q1 EPS reported -$1.59 vs consensus -$9.79 ▲ beat (+83.8%)

Net loss narrowed to $3.5 million ($1.59 per share) versus $10.9 million ($18.75 per share) in Q1 2024.
Continuing merger negotiations with Betaliq; binding exclusivity extended to June 7, 2025.
Optejet user-filled device on track to file for FDA device approval in September 2025.
Cash burn reduced by approximately 70% versus prior year; debt restructuring with Avenue Capital defers payments to October 2025.
Unrestricted cash and equivalents totaled $3.9 million as of March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.